Education
About Us
Working with TipRanks
Follow Us
Pulse Biosciences (PLSE)
NASDAQ:PLSE
PLSE Stock Chart & Stats
$14.04
-$0.27(-1.46%)
At close: 4:00 PM EST
$14.04
-$0.27(-1.46%)
Day’s Range― - ―
52-Week Range$12.56 - $25.00
Previous CloseN/A
Volume31.18K
Average Volume (3M)189.63K
Market Cap
$929.09M
Enterprise Value$936.64M
Total Cash (Recent Filing)$95.21M
Total Debt (Recent Filing)$7.89M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Feb 19, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding67,767,580
10 Day Avg. Volume222,519
30 Day Avg. Volume189,626
Financial Highlights & Ratios
PEG Ratio-4.17
Price to Book (P/B)8.85
Price to Sales (P/S)0.00
P/FCF Ratio-27.88
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue10.89K
Enterprise Value/Gross Profit-2.04K
Enterprise Value/Ebitda-12.36
Forecast
1Y Price Target
$23.50Price Target Upside67.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Recurring Consumables ModelPulse’s business pairs upfront system sales with single-use disposables, creating an installed-base driven recurring revenue stream. If clinical adoption and procedure volumes scale, disposables can deliver durable, high-margin aftermarket sales and predictable revenue over multiple quarters.
Regulatory Progress — FDA IDESecuring an FDA IDE for the NANOPULSE-AF catheter is a structural milestone: it permits controlled pivotal clinical data generation in atrial fibrillation, a large electrophysiology market. Positive trial outcomes could lead to regulatory clearance and commercial entry, materially expanding addressable market.
Low Financial LeveragePulse’s low leverage and modest absolute debt provide financial flexibility to support ongoing R&D and clinical programs without immediate refinancing pressure. This reduces short-term solvency risk and gives management room to execute multi-quarter development and commercialization plans.
Bears Say
Minimal Revenue And Negative Gross ProfitTrailing revenue is effectively negligible and gross margin is negative, indicating the company has not yet reached the scale or pricing needed to cover product costs. Absent structural improvements in adoption, pricing, or unit costs, sustainable profitability is unlikely over the intermediate horizon.
Persistent Heavy Cash BurnLarge and ongoing operating cash outflows materially erode liquidity over quarters without revenue scaling. Continued burn increases the likelihood of financing events or dilution, and constrains the company’s ability to expand commercial footprint or fund multiple simultaneous clinical programs.
Rising Costs And Widening GAAP LossesQuarterly GAAP expenses and net losses have increased as Pulse expands organizational costs and records meaningful stock-based compensation. While spending supports growth, escalating losses pressure equity and runway, potentially forcing program prioritization or spending cuts if revenue fails to ramp.
Pulse Biosciences News
PLSE FAQ
What was Pulse Biosciences’s price range in the past 12 months?
Pulse Biosciences lowest stock price was $12.56 and its highest was $25.00 in the past 12 months.
What is Pulse Biosciences’s market cap?
Pulse Biosciences’s market cap is $929.09M.
When is Pulse Biosciences’s upcoming earnings report date?
Pulse Biosciences’s upcoming earnings report date is Feb 19, 2026 which is in 14 days.
How were Pulse Biosciences’s earnings last quarter?
Pulse Biosciences released its earnings results on Nov 05, 2025. The company reported -$0.203 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.107.
Is Pulse Biosciences overvalued?
According to Wall Street analysts Pulse Biosciences’s price is currently Undervalued.
Does Pulse Biosciences pay dividends?
Pulse Biosciences does not currently pay dividends.
What is Pulse Biosciences’s EPS estimate?
Pulse Biosciences’s EPS estimate is -0.27.
How many shares outstanding does Pulse Biosciences have?
Pulse Biosciences has 67,767,580 shares outstanding.
What happened to Pulse Biosciences’s price movement after its last earnings report?
Pulse Biosciences reported an EPS of -$0.203 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went down -3.319%.
Which hedge fund is a major shareholder of Pulse Biosciences?
Currently, no hedge funds are holding shares in PLSE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulse Biosciences Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$23.50 (67.38% Upside)
$23.50 (67.38% Upside)
Blogger Sentiment
Bullish
PLSE Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 10.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.46%
12-Months-Change
Fundamentals
Return on Equity
-86.99%
Trailing 12-Months
Asset Growth
16.89%
Trailing 12-Months
Company Description
Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
PLSE Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in clinical trials and regulatory approvals, promising initial revenues, and positive clinical outcomes. However, the financials showed increased costs and cash usage, resulting in a higher net loss.View all PLSE earnings summariesPLSE Stock 12 Month Forecast
Average Price Target
$23.50
▲(67.38% Upside)
Technical Analysis
Ownership Overview
73.58% Insiders
2.31% Mutual Funds
0.85% Other Institutional Investors
20.54% Public Companies and
Individual Investors